Metronidazol Braun (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced by their electron transport proteins. This reduction creates nitro radicals that damage microbial DNA and inhibit nucleic acid synthesis, leading to cell death of the targeted bacteria and protozoa.

The dose of Metronidazol Braun is determined by the prescribing clinician based on the type and severity of the infection, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Safety data for metronidazole in pregnancy and lactation are limited. It should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should discuss risks with their healthcare provider, as the drug can be excreted in breast milk.

To order Metronidazol Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Metronidazol Braun offers a broad spectrum against obligate anaerobes and certain protozoa, whereas alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations may lack antiprotozoal activity. Choice of therapy depends on infection site, susceptibility patterns, patient tolerance and potential drug interactions.

Metronidazol Braun should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature for a short period, it may still be used, but it should be returned to refrigeration promptly.

Metronidazol Braun is given by intravenous infusion. The solution is typically diluted in compatible IV fluids and infused over a period determined by the prescriber, often 30‑60 minutes. Administration should follow aseptic technique and institutional infusion guidelines.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic toxicity, and neutropenia. Patients should be monitored for neurological symptoms, skin reactions, liver function changes, and signs of bleeding, especially when combined with anticoagulants.

Metronidazol Braun is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is advised in individuals with severe hepatic or renal impairment, those receiving disulfiram, and patients with a history of seizures or peripheral neuropathy until evaluated by a clinician.